Oncology Biomarkers Market Size, Share, Growth, and Forecast 2032 : BAMG Consulting

Oncology Biomarkers Market Worth $74.62 Billion By 2032, Driven by Precision Oncology, Liquid Biopsy Innovation and Rising Demand for Personalized Cancer Care – New Report by BMAG Consulting

New Delhi, India – September 13, 2026: BMAG Consulting, a global market research and strategic advisory firm, has published its latest report titled “Oncology Biomarkers Market”

The report provides a comprehensive assessment of the global oncology biomarkers market, covering market dynamics, growth drivers, emerging diagnostic technologies, cancer-specific applications, segmentation, regional outlook, competitive landscape, and strategic opportunities across precision medicine and oncology diagnostics.

According to BMAG Consulting, the global Oncology Biomarkers Market was valued at USD 38.14 billion in 2024 and is projected to reach USD 74.62 billion by 2032, registering a CAGR of 8.2% during 2025–2032. North America dominated the market in 2024, supported by advanced healthcare infrastructure, high cancer screening rates, established reimbursement frameworks, and early adoption of next-generation sequencing and companion diagnostic technologies. Asia-Pacific is expected to register the fastest growth during the forecast period.

Download Free Sample

Access an executive summary, market insights, segmentation analysis, regional outlook, competitive intelligence, and strategic opportunities from the Oncology Biomarkers Market Report.

Report: https://bmagconsulting.com/sample/oncology-biomarkers-market

MARKET: KEY INSIGHTS

Market Overview

Oncology biomarkers are becoming increasingly central to modern cancer care as healthcare systems shift from traditional histopathology toward molecularly guided diagnosis, prognosis, treatment selection, and disease monitoring.

The convergence of precision medicine and molecular diagnostics is expanding the role of biomarkers throughout the cancer-care continuum. Pharmaceutical companies are also increasingly developing targeted therapies alongside companion diagnostic tests, creating a reinforcing relationship between oncology drug development and biomarker testing.

The market is being reshaped by liquid biopsy, next-generation sequencing, multi-omics profiling, artificial intelligence, epigenomic analysis, and companion diagnostics. These technologies are enabling clinicians to identify actionable mutations, monitor treatment response, detect recurrence, and potentially identify cancers at earlier stages.

View full report

https://bmagconsulting.com/report/oncology-biomarkers-market

Key Market Drivers & Trends

Growing Global Cancer Burden:
Increasing cancer incidence, population aging, lifestyle-related risk factors, and improved cancer awareness are generating sustained demand for advanced diagnostic and biomarker-based testing.

Rapid Expansion of Precision Oncology:
Biomarker testing enables oncologists to match patients with targeted therapies and immunotherapies according to the molecular characteristics of individual tumors, supporting more personalized treatment strategies.

AI and Liquid Biopsy Convergence:
Artificial intelligence and machine learning are increasingly being integrated with liquid biopsy platforms to interpret circulating tumor DNA, circulating tumor cells, exosomes, methylation patterns, and other molecular signals.

Growing Adoption of Multi-Cancer Early Detection:
Methylation-based signatures, fragmentomics, and other molecular approaches are creating opportunities for blood-based tests capable of screening for signals associated with multiple cancer types.

Expansion of Companion Diagnostics:
As targeted oncology therapies become more prevalent, pharmaceutical companies are increasingly partnering with diagnostic developers to establish companion tests that identify patients most likely to benefit from specific treatments.

Increasing Use of Biomarkers for Treatment Monitoring:
Biomarkers are moving beyond initial diagnosis and treatment selection into real-time monitoring of therapeutic response, minimal residual disease, recurrence, and disease progression.

Advances in Multi-Omics Profiling:
The integration of genomic, proteomic, epigenomic, and other biological data is enabling increasingly comprehensive characterization of tumors and supporting biomarker discovery.

High Cost and Regulatory Complexity Remain Challenges:
Advanced biomarker tests can require sophisticated laboratory infrastructure, specialized reagents, trained personnel, extensive clinical validation, and regulatory approval, which can restrict access and increase commercialization costs.

Segmentation Insights

The Oncology Biomarkers Market is segmented based on:

By Biomarker Type

• Genomic Biomarkers

• Proteomic Biomarkers

• Genetic Biomarkers

• Epigenetic Biomarkers

• Others

By Cancer Type

• Breast Cancer

• Lung Cancer

• Colorectal Cancer

• Prostate Cancer

• Ovarian Cancer

• Others

By Application

• Diagnostics

• Prognostics

• Drug Discovery & Development

• Personalized Medicine

• Risk Assessment

• Others

By Technology

• Genomics

• Proteomics

• Imaging Technologies

• Bioinformatics

• Others

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

Regional Insights

North America held the largest share of the global oncology biomarkers market in 2024. The region benefits from advanced healthcare infrastructure, high healthcare expenditure, established reimbursement systems, leading diagnostic companies, major cancer centers, and early adoption of next-generation sequencing, liquid biopsy, and companion diagnostics.

The United States is a major innovation hub, with strong collaboration between pharmaceutical companies, diagnostic developers, academic institutions, and reference laboratories. Regulatory support for innovative biomarker technologies is also helping accelerate commercialization.

Asia-Pacific is expected to record the fastest growth during the forecast period. Increasing cancer incidence, expanding diagnostic laboratory networks, rising healthcare expenditure, and government-supported cancer screening programs in markets including China, India, and Japan are creating significant opportunities.

Europe remains an important market, supported by coordinated cancer-control programs, established public-health screening infrastructure, advanced molecular diagnostics capabilities, and increasing adoption of biomarker-based testing.

Competitive Landscape

The global oncology biomarkers market is characterized by competition among major diagnostics and life sciences companies, precision oncology specialists, and emerging liquid-biopsy and multi-omics technology developers.

Key companies profiled in the BMAG Consulting report include:

• F. Hoffmann-La Roche Ltd.

• Thermo Fisher Scientific Inc.

• Illumina, Inc.

• QIAGEN N.V.

• Abbott Laboratories

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• Guardant Health, Inc.

• Myriad Genetics, Inc.

• Merck KGaA

• Exact Sciences Corporation

• Revvity, Inc.

• Sysmex Corporation

• Natera, Inc.

Competitive differentiation increasingly depends on genomic panel breadth, analytical sensitivity, clinical validation, companion diagnostic approvals, liquid-biopsy capabilities, AI-enabled interpretation, multi-omics integration, pharmaceutical partnerships, and regulatory expertise.

Recent Industry Developments

• In January 2026, Guardant Health received FDA approval for Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may be eligible for a targeted combination therapy. The approval marked the test's 25th companion diagnostic indication across tumor types.

• In May 2026, Guardant Health received FDA approval for an updated Guardant360 Liquid CDx panel, integrating genomic and epigenomic insights with an expanded genomic footprint to broaden comprehensive blood-based tumor profiling for patients with advanced cancer.

About BMAG Consulting

BMAG Consulting is a global market research and strategic advisory firm providing actionable market intelligence across healthcare, life sciences, technology, chemicals, energy, food & beverage, automotive, aerospace & defense, and other high-growth industries.

BMAG Consulting provides market sizing, competitive intelligence, strategic consulting, opportunity assessment, industry forecasting, and customized research solutions to help organizations identify emerging opportunities and make informed business decisions.

Media Contact

BMAG Consulting
Email: sales@bmagconsulting.com
Website: https://bmagconsulting.com